07 Febrero 2015
Administrator

Added by

gregorcuba

Item Type

Journal Article

Title

A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design

Author

Torre-Amione, Guillermo

Author

Bourge, Robert C

Author

Colucci, Wilson S

Author

Greenberg, Barry

Author

Pratt, Craig

Author

Rouleau, Jean-Lucien

Author

Sestier, Francois

Author

Moyé, Lemuel A

Author

Geddes, John A

Author

Nemet, Agnes J

Author

Young, James B

 

 

 

Abstract

BACKGROUND: Evidence has accumulated regarding the importance of inflammatory mediators in the development and progression of heart failure (HF). Although targeted anticytokine treatment strategies, specifically antitumour necrosis factor-alpha, have yielded disappointing results, this may simply reflect the redundancy of the cytokine cascade and the fact that antitumour necrosis factor-alpha therapies do not stimulate increased activity of the anti-inflammatory arm of the immune system. Ex vivo exposure of autologous blood to controlled oxidative stress and subsequent intramuscular administration is a device-based procedure shown in experimental studies to have a broad-spectrum effect on a number of immune mediators. These studies have demonstrated that this approach downregulates inflammatory cytokines, whereas several anti-inflammatory cytokines are increased. In a feasibility study of 73 patients with moderate to severe HF, active therapy (versus placebo) had a significant benefit on both mortality and hospitalization, and was not associated with adverse hemodynamic or metabolic effects. METHODS: The Advanced Chronic heart failure CLinical Assessment of Immune Modulation therapy (ACCLAIM) trial is a multicentre, randomized, double-blind, placebo-controlled clinical trial of New York Heart Association functional class II to IV chronic HF patients with left ventricular ejection fraction of 30% or less. Enrolling approximately 2400 subjects at 177 sites, the primary end point of the study was the cumulative incidence (time to first event) of the combined end point of total mortality or hospitalization for cardiovascular causes. The study was completed in late 2005, when 701 primary end point events had occurred and all patients had been treated for six months. CONCLUSIONS: If the ACCLAIM trial confirms earlier results, this approach represents a novel nonpharmacological treatment for HF that targets a pathogenic mechanism contributing to progression of this syndrome not addressed by current therapies.

Publication

The Canadian Journal of Cardiology

Volume

23

Issue

5

Pages

369-376

Date

Apr 2007

Journal Abbr

Can J Cardiol

ISSN

0828-282X

Short Title

A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure

URL

http://www.ncbi.nlm.nih.gov/pubmed/17440642

Accessed

2010-02-24 19:20:55

Library Catalog

NCBI PubMed

Extra

PMID: 17440642

 

 

Ver artículo en ventana emergente

07 Febrero 2015
Administrator

Added by

gregorcuba

Item Type

Journal Article

Title

[Application of medical ozone in acute exacerbations of hepatitis B of 1 case of lymphoma chemotherapy]

Author

An, Liangmin

Author

Guo, Yabing

Author

Peng, Jie

Author

Meng, Fanyi

Author

Zhou, Fuyuan

Abstract

Objective: To explore the application of the medical ozone in acute exacerbations of hepatitis B of 1 case of lymphoma chemotherapy. Methods: 1 patient who suffering with chronic hepatitis B liver cirrhosis and non-Hodgkin's lymphoma (NHL) appeared hepatitis B virus activity and liver failure in the course of chemotherapy (CHOP program) (Child-Pugh score 11 points) , the function of liver was mitigated after the treatment of Lamivudine Tablets and symptomatic support, but the lymphoma recurrence after 4 months. Rituximab and 2 times CHOP chemotherapy, increased the liver damage; increase with ozone treatment (self-blood therapy /ozone rectal infusion), continued to complete the original program of chemotherapy. Results: Acute exacerbations of hepatitis B of 1 case of lymphoma chemotherapy with ozone treatment increase in the original treatment, made a significant effect of lymphoma, no liver failure and the liver function recovery (Child-Pugh score 7 points) .Conclusion: Medical ozone can be activated the effect of cell antioxidant capacity and free radical scavenging and improve the microcirculation, protect the liver mitigate the damage of chemotherapy. Key Words Medical ozone Hepatitis B Non Hodgkin lymphoma Drug-induced hepatitis

Publication

China Modern Medicine

Issue

13

Date

2009

Journal Abbr

China Modern Med

Language

Chinese

DOI

CNKI:SUN:ZGUD.0.2009-13-056

ISSN

1674-4721

URL

http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZGUD200913056.htm

Tags

 

 

 

Ver artículo en ventana emergente

07 Febrero 2015
Administrator

Added by

gregorcuba

Item Type

Journal Article

Title

[Cellular immunity indexes and influence of ozonetherapy on immune system at patients with viral hepatitis B]

Author

Maukayeva, S B

Abstract

Indexes of cellular immunity at patients with viral hepatitis В (HBV-infection) and their dynamic due to ozonetherapy are studied. 60 patients with viral hepatitis В are examined. 30 patients were treated by ozone. 30 patients were treated by traditional therapy. Results of investigation revealed depression of immune cells production. Use of ozone in treatment of patients with viral hepatitis В results in normalization of cellular immunity indexes.

Publication

Vestnik Meditsinskogo tsentra Upravleniya delami Prezidenta Respubliki Kazakhstan

Issue

4

Pages

81-85

Date

2009

Journal Abbr

Vestnik Meditsinskogo tsentra Upravleniya delami Prozid

Language

Russian

ISSN

http://www.mcudprk.kz/JURNAL_MC_UDP_RK/4-2009.pdf

URL

 

Tags

 

 

 

Ver artículo en ventana emergente